A new series of 1-(5-(2-tolyloxyquinoline-3-yl)-2-(pyridine-4-yl)-1,3,4-oxidiazol-3(2
H
)-yl)ethanones were synthesized from cyclisation of
N
’-((2-(
p
-tolyloxy)quinoline-3-yl)methylene) isonitonohydrazide in acetic unhydride at reflux condition for 3-4 hr. The structures of the new compounds were confirmed by elemental analyses as well as IR,
1
H NMR and mass spectral data. All the synthesized compounds were screened for their antibacterial activities against various bacterial strains. Several of these compounds showed potential antibacterial activity.
INTRODUCTION
Quinoline ring systems represent a major class of heterocycles as they occur in various natural products especially in alkaloids.
1
It possesses diverse biological and physiological activities such as antimalarial,
2
anti-inflammatory,
3
antitumor,
4
DNA binding capacity,
5
antibacterial properties.
6
Recently, quinoline has been employed in the study of bio-organic and bio-organometallic processes.
7
There are many quinoline-based compounds which are known to exhibit anti-TB properties. Compound TMC207
8
bearing a bulky biaryl side chain at position C3, is a highly potent anti-TB agent and is currently in phase II clinical trials. In particular 2-chloroquinoline-3-carbaldehyde has been used as a key intermediate for the synthesis of variety of medicinally valuable compounds.
9
1,3,4-oxadiazole is widely exploited for various applications. A number of therapeutic agents such as HIV-integrase inhibitor raltegravir, a nitrofuran antibacterial furamizole, a potent PDF inhibitor BB-83698, antihypertensive agents Tiodazosin and Nesapidil are based on 1,3,4-oxadiazole moiety. The 1,3,4-oxadiazole undergoes number of reactions including elctrophillic substitution, nucleophilic substitution, thermal and photochemical. The substituted oxadiazoles are heterocyclic compounds, which serve both as biomimetic and reactive pharamacophores and many are key elements with potential biological activities
10
-
12
such as pesticidal,
13
antiperipheral vasomotility,
14
CNS stimulant, anti-inflammatory, hypertensive,
15
insecticidal,
16
bactericidal,
17
hypoglycemic,
18
-
19
analgesic, anticonvulsive, antiemetic, diuretic,
20
muscle relaxant,
21
-
22
herbicidal
23
-
24
and fungicidal activity.
25
-
26
Isoniazide (INH) is widely applied as first-line drugs for the treatment of tuberculosis, usually in combination with other drugs. Modifying either of these molecules has been a challenge taken up by several research groups.
27
INH prevents a mycolic acid biosynthesis by inhibiting a 2-trans-enoyl-acyl carrier protein reductase (InhA) that belongs to the FAS-II (fatty acid synthetase II) system.
28
In our continuous program in the search of new potent and safe synthesis of biologically active heterocycles,
29
-
30
we have planned to synthesize some new series of various substituted 1-(5-(2-(
p
-tolyloxy)quinoline-3-yl)-2-(pyridine-4-yl)-1,3,4-oxadiazol-3(2
H
)-yl)ethanones by oxidative cyclisation of
N
-((2-(
p
-tolyloxy)quinoline-3-yl)methylene) isonitonohydrazide using by cyclisation using acetic anhydride under reflux condition and evaluating their antibacterial activity against the standard drug Streptomycin and Ampicillin.
RESULT AND DISCUSSION
- Chemistry
The synthetic work was carried out beginning from 2-chloro-3-formylquinoline
1(a-j)
according to
1
. The reaction of 2-chloro-3-formylquinoline
1(a-j)
with p-Cresol in presence of K
2
CO
3
/DMF at 80-90 ℃ for 4-5 hr gave substituted 2-(
p
-tolyoxy)quinoline-3-carbaldehyde
2(a-j)
. Further reaction of isonicotinohydrazide
3
with substituted 2-(
p
-tolyoxy)quinoline-3-carbaldehyde
2(a-j)
gave corresponding
N
’-((2-(
p
-tolyloxy)quinoline-3-yl) methylene)isonitonohydrazide
4(a-j)
in acetic acid in ethanol at room temperature. followed by cyclisation of
N
-((2-(
p
-tolyloxy)quinoline-3-yl)methylene isonitonohydrazide using acetic anhydride to gave our targeted product i.e. 1-(5-(2-(
p
-tolyloxy)quinoline-3-yl)-2-(pyridine-4-yl)-1,3,4-oxadiazol-3(2
H
)-yl)ethanone
5(a-j)
. All the synthesized compounds were characterized by their physical and spectral data (IR,
1
H-NMR, Mass).
- Spectral analysis
The structures of the synthesized compounds were confirmed by spectral analysis (IR,
1
H NMR and Mass). The IR spectrum of compound
2a
showed a peak at 1690 cm
-1
due to C=O stretch. In
1
H NMR spectrum it exhibited two singlets, one at δ 2.41 due to -CH
3
protons and second at δ 10.65 due to -CHO proton. Mass spectrum was consistent with assigned structure showing M +1) peak at m/z = 264.1. The structure of
4a
is interpreted from spectroscopic data, IR spectra of compound
4a
reveals absorption band in the region 1560 cm
-1
corresponding to -C=N stretching at 1640 cm
-1
. The
1
H NMR spectra of
4a
exhibits a sharp singlet at δ 2.01 for -CH
3
and one broad singlet at δ 10.50 of -NH. The pyridine ring protons appeared doublet at δ 8.92 and 8.75 respectively. C
4
- proton of quinoline nuclei appears as a singlet at δ 8.33. All other aromatic protons arise at respective position. The IR spectrum of compound
5a
showed absorption peak at 1510 cm
-1
due to C=N stretching vibrations. The peak at 1665 cm
-1
due to the N-COCH
3
confirms the formation of N-acyl oxadiazole ring, its
1
H NMR spectrum revealed a singlet at δ 4.61 due to CO-CH
3
also one singlet appears at 6.95 ppm due -CH of oxadiazole ring and rest of the protons appears at repective position.
Physical data of the compounds5(a-j)
Physical data of the compounds 5(a-j)
- Antibacterial activity
The antibacterial activities of the synthesized compounds were determined by the well-diffusion method.
31
In present work, two Gram positive bacteria,
Bacillus subtilis
(ATCC 6633),
Staphylococcus aureus
(ATCC 25923) and two Gram negative bacteria,
Salmonella typhimurium
(ATCC 23564),
Pseudomonas aeruginosa
(ATCC 27853) were used to investigate the antibacterial activities. The bacterial liquid cultures were prepared in fusion broth for their activity tests. The compounds were dissolved in DMSO at concentration of 1 mgmL
-1
. Antibacterial activity of DMSO against the test organisms was investigated, and was found to be nil. Molten nutrient agar (15 cm
3
) kept at 45 ℃, was then poured into the Petri dishes and allowed to solidify. Ten millimeter diameter holes were then punched carefully using a sterile cork borer and completely filled with the test solutions. The plates were incubated for 24 hr at 37 ℃. After 24 hr, the inhibition zone that appeared around the holes in each plate was measured. Antibacterial activity was determined by measuring the diameter of inhibition zone and examining the minimal inhibitory concentration (MIC). Activity of each compound was compared with streptomycin and ampicillin as standards. The observed data of antibacterial activity of compounds and the standard drugs is given in
2
. The compounds
5e
,
5f
,
5i
and
5j
show excellent antibacterial activity against Gram positive bacterial strains. Likewise compounds
5a
,
5c
and
5g
showed excellent activity against Gram negative bacterial strains.
The Minimum Inhibitor concentrations of tested compounds5(a-j)in μg/mL
aZone of inhibition, bMinimum inhibitory concentration in μg/mL
EXPERIMENTAL SECTION
Melting points were recorded in open capillaries in liquid paraffin bath and are uncorrected. The progress of reaction was monitored by thin layer chromatography using silica gel (Merck). IR spectra were recorded on a SHIMADZU-FT-IR spectrophotometer in KBr disc.
1
H NMR spectra were recorded on BRUKER ADVANCE-II 400 NMR spectrophotometer in DMSO-
d6
as a solvent and TMS as an internal standard. Peak values are shown in d ppm. Mass spectra were recorded on a PEP-SCIUX-APIQ pulsar (electron pre-ionization) mass spectrometer. Elemental analyses were performed on Perkin-Elmer EAL-240 elemental analyzers.
- General procedure for the synthesis of 2-(p-tolyloxy) quinoline-3-carbaldehydes 2(a-j)
To the mixture of
p
-cresol (3.7 gm, 0.034 mol) and K
2
CO
3
(12.8 gm, 0.093 mol) in DMF, compound
1a
(6 gm, 0.031 mol) was added and the reaction mixture was stirred at 80-90 ℃ for 4-5 hr. The completion of the reaction was monitored on TLC. After completion of the reaction, ice cold water (50 ml) was poured on the reaction mixture & the solid thus obtained was filtered off and washed with water, further the compound was recrystallized in ethyl acetate.
- 2-(p-tolyloxy)quinoline-3-carbaldehyde (2a)
IR-(KBr, cm
-1
): 1690(C=O), 1610, 1525(C=C);
1
H NMR-(400 Hz, DMSO-
d6
): δ 10.65(s, 1H, -CHO), 8.72(s, 1H, Ar-H), 7.89(d,
J
= 8 Hz, 1H, Ar-H), 7.73(d,
J
= 8 Hz, 1H, Ar-H), 7.70(t, 1H, Ar-H), 7.45(t, 1H, Ar-H), 7.27(d,
J
= 8 Hz, 2H, Ar-H), 7.18(d,
J
= 8 Hz, 2H, Ar-H), 2.41(s, 3H, -CH
3
); ES-MS (m/z): 264.4 (M+1).
- General procedure for the synthesis of (E)-N’-((2-tolyloxy) quinoline-3-yl) methylene) isonicotinohydrazide 4(a-j)
An equimolar mixture of 2-chloro-3-formyl quinoline
1a
(0.004 mol) and isonicotinohydrazide
3
(0.004 mol) in 10 mL ethanol containing few drops of glacial acetic acid was strired at room temperature. After completion of reaction (checked by TLC), the excess of solvent was removed on rotary evaporator to yield solid which was washed with petroleum ether followed by crystallization from ethanol.
- (E)-N’-((2-tolyloxy) quinoline-3-yl) methylene)isonicotinohydrazide (4a)
IR (KBr, cm
-1
): 2980 (-NH), 1560 (C=N), 1513 (C=C);
1
H NMR (400 Hz, DMSO-
d6
): δ 10.72 (s, 1H, -NH), 8.90 (s, 1H), 8.77 (d,
J
= 7.92 Hz, 3H, Ar-H), 7.75-7.80 (m, 4H, Ar-H), 7.26 (t,
J
= 10.94 Hz, 2H, Ar-H), 7.19 (dd,
J
= 8.21 & 4.24 Hz, 4H, Ar-H) 2.30 (s, 3H, Ar-CH
3
), ES-MS (m/z): 383(M+1); Anal. Calcd. C
23
H
18
N
4
O
2
C, 72.24; H, 4.74; N, 14.65, found C,72.22; H, 4.80; N, 14.56%.
- (E)-N’-((2-tolyloxy)-6-ethoxyquinoline-3-yl)methylene) isonicotinohydrazide (4h)
IR (KBr, cm
-1
) : 3009 (-NH), 1577 (C=N), 1510 (C=C);
1
H NMR (400 Hz, DMSO-
d6
): δ 10.79 (s, 1H, -NH), 8.92 (s, 1H), 8.73 (d,
J
= 8.21 Hz, 2H, Ar-H) 7.84-7.89 (dd, 4H, Ar-H), 7.21 (t,
J
= 11.30 Hz, 2H, Ar-H), 7.16 (dd,
J
= 8.44 & 4.66Hz, 4H, Ar-H), 2.67 (s, 3H, Ar-CH
3
), 1.41 (s, 3H, -CH
3
); ES-MS (m/z): 427 (M+1); Anal. alcd. C
25
H
22
N
4
O
3
C, 70.41; H, 5.20; N, 13.14, found C, 70.43; H, 5.30; N, 13.21%.
- General Procedure for the Synthesis of Substituted 1-(5-(2-(p-tolyloxy)quinoline-3-yl)-2-(pyridine-4-yl)-1,3,4-oxadiazol-3(2H)-yl)ethanones 5(a-j)
N
’-((2-(
p
-tolyloxy)quinoline-3-yl)methylene)isonicitinohydrazide (0.1 gm, 0.00028 mol)
4a
was dissolved in 10 ml of acetic anhydride. The reaction mixture was heated in an oil bath for 3-4 h at 120 ℃ and left for overnight. 10 ml cold water was slowly added to the flask and the separated product was filtered and washed with water, dried under vacuum and recrystallized from ethanol.
- 1-(5-(2-(p-tolyloxy)quinolin-3-yl)-2-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl)ethanone (5a)
IR KBr: 1665 (N-CO-CH
3
); 1610 (C=N) cm
-1
;
1
H NMR (400 MHz, CDCl
3
): δ 2.332 (s, 3H, Ar-CH
3
); 4.621 (s, 3H, N-CO-CH
3
); 6.956 (s; 1H, -CH); 7.115 (d,
J
=8.0 Hz, 2H, Ar-H); 7.244 (d,
J
=8.0 Hz, 2H, Ar-H); 7.623-7.851 (m, 6H, Ar-H); 8.151 (s, 1H, quinoline C
4
-H); 9.022 (s, 2H, pyridine); Mass(m/z): 425 (M+1).
- 1-(5-(2-(p-tolyloxy)-6-methylquinolin-3-yl)-2-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl) ethanone (5b)
IR KBr: 1688 (N-CO-CH
3
); 1593 (C=N) cm
-1
;
1
H NMR (400 MHz, DMSO): δ 2.344 (s, 3H, Ar-CH
3
); 2.275 (s, 3H, Ar-CH
3
); 3.829 (s, 3H, NCOCH
3
); 6.945 (s, 1H, -CH); 7.107-7.166 (m, 3H, Ar-H); 7.275 (d,
J
=8.4 Hz, 2H, Ar-H); 7.861 (dd,
J
=4.6 & 6.0 Hz, 3H, Ar-H); 8.026 (d,
J
=8.8 Hz, 1H, Ar-H); 8.772-8.821(d, 2H, pyridine); 8.962(s, 1H, quinoline C
4
-H); Mass(m/z): 439.0(M+1).
- 1-(5-(2-(p-tolyloxy)-7-methylquinolin-3-yl)-2-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl)ethanone (5c)
IR KBr: 1649 (N-CO-CH
3
); 1556 (C=N) cm
-1
;
1
H NMR (400 MHz, DMSO): δ 2.154 (s, 3H, Ar-CH
3
); 2.165 (s, 3H, Ar-CH
3
); 3.984 (s, 3H, NCOCH
3
); 6.546 (s, 1H, -CH); 7.166-7.245 (m, 4H, Ar-H); 7.315 (d,
J
=8.4 Hz, 1H, Ar-H); 7.748 (dd,
J
=3.4 & 7.2 Hz, 3H, Ar-H); 8.126 (d,
J
=7.8 Hz, 1H, Ar-H); 8.845-8.875 (d, 2H, pyridine); 8.987 (s, 1H, quinoline C
4
-H); Mass(m/z): 439.3(M+1).
- 1-(5-(2-(p-tolyloxy)-7-methoxyquinolin-3-yl)-2-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl)ethanone (5g)
IR KBr: 1687 (N-CO-CH
3
); 1510 (C=N) cm
-1
;
1
H NMR (400 MHz, DMSO): δ 2.54 (s, 3H, Ar-CH
3
); 3.651 (s, 3H, Ar-OCH
3
); 3.914 (s, 3H, NCOCH
3
); 6.646 (s, 1H, -CH); 6.924-7.145 (m, 3H, Ar-H); 7.245 (d,
J
=8.4 Hz, 2H, Ar-H); 7.658 (dd,
J
=2.6 & 6.8 Hz, 3H, Ar-H); 8.646 (d,
J
=8.8 Hz, 1H, Ar-H); 8.845-8.895 (d, 2H, pyridine); 8.912 (s, 1H, quinoline C
4
-H); Mass(m/z): 455.1(M+1).
- 1-(5-(2-(p-tolyloxy)-7-ethoxyquinolin-3-yl)-2-(pyridin-4-yl)-1,3,4-oxadiazol-3(2H)-yl)ethanone (5h)
IR KBr: 1667 (N-CO-CH
3
); 1556 (C=N) cm
-1
;
1
H NMR (400 MHz, DMSO): δ 2.464 (s, 3H, Ar-CH
3
); 2.563 (t, 3H,CH
2
CH
3
); 3.456 (q, 2H, OCH
2
); 3.814 (s, 3H, NCOCH
3
); 6.512 (s, 1H, -CH); 6.958-7.165 (m, 3H, Ar-H); 7.145 (d,
J
=7.2 Hz, 2H, Ar-H); 7.456 (dd,
J
=4.2 & 7.6 Hz, 3H, Ar-H); 8.245 (d,
J
=8.2 Hz, 1H, Ar-H); 8.312 (s, 1H, quinoline C
4
-H); 8.614-8.814 (d, 2H, pyridine); Mass(m/z): 469.1 (M+1).
Acknowledgements
The authors are thankful to to The Head, Department of Chemistry, Dr. Babasaheb Ambedkar Marathwada University, Aurangabad, for his valuable support and laboratory facilities. And RSJ is thankful to University Grants Commission, New Delhi, for awarding the fellowship.
MethCohn O.
,
Narine B.
,
Tarnowski B.
,
Hayes R.
,
Keyzad A.
,
Rhouti S.
,
Robinson A.
1981
J. Chem. Soc. Perkin Trans.
1
2509 -
DOI : 10.1039/p19810002509
Sukhova N. M.
,
Lidak M.
,
Zidermane A.
,
Pelevina I. S.
,
Voronia S. S.
1989
Khim. Farm. Zh.
23
1226 -
Patel H. V.
,
Vyas K. V.
,
Fernandes P. S.
1990
Ind. J. Chem.
29
(B)
836 -
Andries K.
,
Verhasselt P.
,
Guillemont J.
,
Goehlmann H. W. H.
,
Neefs J. M.
,
Winkler H.
,
Van Gestel J.
,
Timmerman P.
,
Zhu M.
,
Lee E.
,
Williams P.
,
De Chaffoy D.
,
Huitric E.
,
Hoffner S.
,
Cambau E.
,
Truffot-Pernot C.
,
Lounis N.
,
Jarlier V. A.
2005
Science
307
223 -
DOI : 10.1126/science.1106753
Joseph J. P.
,
Harry L. Y.
1961
U.S. Patent 3,141,022
Chem. Abstr. 1964, 61, 8317b.
Ansel P. S.
1959
U.S. Patent 2,883,391
Chem. Abstr. 1959, 53, 16157g.
Hiroshi K.
,
Isaq H.
,
Shigeki O.
1969
Zassokenkyn
Chem. Abstr. 1970, 73, 108544b.
8
46 -
Derappe C.
,
Rips R.
,
Albert O.
,
Aurousseau M.
1968
Chim. Ther.
Chem. Abstr. 1968, 69, 106626y.
3
181 -
Deshmukh A. A.
,
Sattur P. B.
,
Sheth U. K.
1976
Indian. J. Exp. Biol.
4
166 -
SenGupta A. K.
,
Garg M.
,
Chandra U.
1979
J. Indian Chem. Soc.
56
1230 -
Chiyomaru I.
,
Takita K.
,
Ito H.
Jap. Pat. 1972, 72 07, 549
Kumiai Chem. Ind. Co. Ltd.
Chem. Abstr. 1972, 77, 549.
O Neal J. B.
,
Rosen H.
,
Russel P. B.
,
Adams A. C.
,
Blumenthal A.
1962
J. Med. Pharm. Chem.
Chem. Abstr. 1962, 57, 9168c.
5
617 -
DOI : 10.1021/jm01238a019
Kurzer F.
1974
Org. Compd. Sulphur, Selenium, Tellurium
4
417 -
Thoma J.
Ger. Pat. 2,403, 357/1974
Chem. Abstr. 1974, 81, 136153g.
Turner S. R.
1978
Ger. Pat. 1978, 2, 727, 146
Colman Products Ltd.
Chem. Abstr. 1978, 88, 105357s.
Hodogaya, Chemical Co. Ltd.
Jap. Pat. 1980, 80, 27024
Chem. Abstr. 1980, 93, 232719q.
Hakko Chem. Ind. Co. Ltd.
Brit. Pat. 1,266,542/1972
Chem. Abstr. 1972, 77, 5474g.
Misato T.
,
Ko K.
,
Honma Y.
,
Konno K.
,
Taniyama E.
Jap. Pat. 1977, 772508
Inst. Phys. Chem. Res.
Chem. Abstr. 1977, 87, 147054.
Marrakchi H.
,
Laneelle G.
,
Quemard A.
2000
Microbiology
146
296 -